Pfizer holds lead in erectile dysfunction market as Viagra sales fall

on Feb14
by | Comments Off on Pfizer holds lead in erectile dysfunction market as Viagra sales fall |

Despite generic competition from other drugmakers, Pfizer has been able to maintain a significant market share thanks, in part, to launching its own generic version of the blue, diamond-shaped pill.

In late 2017, Pfizer announced it would produce a generic version, called sildenafil, at half the cost of the brand name. The company also said at the time it would offer new discount programs and increase its copayment card discounts to make the brand version more accessible to patients.

According to GoodRx, 65 percent of ED prescriptions filled from Dec. 1, 2018, to Jan. 31, 2019, were for Viagra or its generic version. Thirty percent of prescriptions were for rival Cialis and its generic, tadalafil. Levitra and generic vardenafil came in third at 5 percent of the market.

Additionally, the gap between prescriptions filled for brand-name versus generics is large. Ninety percent of the prescriptions filled over that same two-month time period were for Pfizer’s generic version, while only 10 percent prescribed were for the brand name, according to GoodRx.

“The data can’t explain the reason behind why people take the generic over the brand, or vice versa,” said Tori Marsh, data and content manager at GoodRx. “But since generic Viagra is more affordable than the brand it’s likely that cost is a factor here.”

Marsh added most health insurers require that members be prescribed a generic when there is one available, and that pharmacies dispense the generic.



Previous postAmazon cancels plan to create a New York headquarters Next postA look at the Airbus A380, inside and out, a craft that fliers love


Los Angeles Financial times


Copyright © 2021 Los Angeles Financial times

Updates via RSS
or Email